Is Daiichi Sankyo's Next Generation Flu Therapy Ready To Shake Up The Japanese Market?
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Central Social Insurance Medical Council (Chuikyo) announced Sept. 29 it would add Daiichi Sankyo's Inavir (laninamivir) to Japan's National Health Insurance Drug Price List, clearing the way for the first launch of the next-generation inhaler flu treatment on Oct. 19